Antiphospholipid Syndrome (APS) Clinical Trial
Official title:
A Single Center, Randomized Controlled, Open Trial Exploring the Regulatory Effect of Telitacicept on Antibody Titers in Primary Antiphospholipid Syndrome Patients Carrying High-risk Antiphospholipid Antibody Profiles
The purpose of this study is to evaluate the regulatory effect of Telitacicept on antibody titers in primary antiphospholipid syndrome patients carrying high-risk antiphospholipid antibody profiles.
This is a single center, randomized controlled trial in Ruijin Hospital. The enrolled patients will be randomized in a 1: 1 ratio to receive either SOC+Telitacicept or SOC treatment.Telitacicept is administered subcutaneously at a dose of 160mg once a week for 48 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06371417 -
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
|
Phase 1 | |
| Recruiting |
NCT02595346 -
Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT01787305 -
Pilot Study of Gut Commensals in Antiphospholipid Syndrome
|